6 de abril de 2020
16 de junio de 2014
- Comunicado -

TEENs Study Shows Achieving Target Blood Sugar Levels is Associated with Better Quality of Life for Young People with Ty


1) Global Assessment of Factors Associated with Target Glycemic Control in
Youth with Type 1 Diabetes (T1D): the TEENs Study (Laffel et al. Oral presentation,
June 13, 6:00 pm PST, abstract # 32-OR)
2) Opportunities to Enhance Diabetes-specific Quality of Life (QoL) in Youth
with Type 1 Diabetes (T1D): the Global TEENs Study (Anderson et al. Oral presentation,
June 16, 9:00 am PST, abstract # 259-OR)
3) Diabetes-specific Health-related Quality of Life (QoL) in a Sample of US
Youth with Type 1 Diabetes (T1D) in the TEENs Study (Anderson et al. Poster
presentation, June 14, 11:30 am to 1:30 pm PST, abstract # 1247-P)



About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris and in New York .

Forward Looking Statements

Sanofi Forward Looking Statements

(CONTINUA)